The oral-gut microbiome axis in health and disease.

Gilbert, J. A. et al. Current understanding of the human microbiome. Nat. Med. 24, 392–400 (2018).

pubmed: 29634682 pmcid: 7043356 doi: 10.1038/nm.4517

Honda, K. & Littman, D. R. The microbiota in adaptive immune homeostasis and disease. Nature 535, 75–84 (2016).

pubmed: 27383982 doi: 10.1038/nature18848

Gilbert, J. A. et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 535, 94–103 (2016).

pubmed: 27383984 doi: 10.1038/nature18850

Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).

pubmed: 29209090 pmcid: 5716994 doi: 10.1038/s41467-017-01973-8

Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).

pubmed: 17183312 doi: 10.1038/nature05414

Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat. Med. 21, 895–905 (2015).

pubmed: 26214836 doi: 10.1038/nm.3914

Paun, A., Yau, C. & Danska, J. S. The influence of the microbiome on type 1 diabetes. J. Immunol. 198, 590–595 (2017).

pubmed: 28069754 doi: 10.4049/jimmunol.1601519

Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780–13785 (2007).

pubmed: 17699621 pmcid: 1959459 doi: 10.1073/pnas.0706625104

Kilian, M. The oral microbiome—friend or foe? Eur. J. Oral. Sci. 126, 5–12 (2018).

pubmed: 30178561 doi: 10.1111/eos.12527

Baker, J. L. & Edlund, A. Exploiting the oral microbiome to prevent tooth decay: has evolution already provided the best tools? Front. Microbiol. 9, 3323 (2018).

pubmed: 30687294 doi: 10.3389/fmicb.2018.03323

Sedghi, L., DiMassa, V., Harrington, A., Lynch, S. V. & Kapila, Y. L. The oral microbiome: role of key organisms and complex networks in oral health and disease. Periodontol 2000 87, 107–131 (2021).

pubmed: 34463991 pmcid: 8457218 doi: 10.1111/prd.12393

Pathak, J. L., Yan, Y., Zhang, Q., Wang, L. & Ge, L. The role of oral microbiome in respiratory health and diseases. Respir. Med. 185, 106475 (2021).

pubmed: 34049183 doi: 10.1016/j.rmed.2021.106475

Irfan, M., Delgado, R. Z. R. & Frias-Lopez, J. The oral microbiome and cancer. Front. Immunol. 11, 591088 (2020).

pubmed: 33193429 pmcid: 7645040 doi: 10.3389/fimmu.2020.591088

Hajishengallis, G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat. Rev. Immunol. 15, 30–44 (2015).

pubmed: 25534621 pmcid: 4276050 doi: 10.1038/nri3785

Hajishengallis, G. & Chavakis, T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nat. Rev. Immunol. 21, 426–440 (2021). This review highlights the potential causal links between periodontitis and other chronic inflammation-driven disorders, emphasising their multifaceted mechanistic causality.

pubmed: 33510490 pmcid: 7841384 doi: 10.1038/s41577-020-00488-6

Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492–506 (2020).

pubmed: 32433595 pmcid: 7264227 doi: 10.1038/s41422-020-0332-7

Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. 19, 55–71 (2021).

pubmed: 32887946 doi: 10.1038/s41579-020-0433-9

Hou, K. et al. Microbiota in health and diseases. Signal. Transduct. Target. Ther. 7, 135 (2022).

pubmed: 35461318 pmcid: 9034083 doi: 10.1038/s41392-022-00974-4

Fedoruk, M. J. & Hong, S. in Encyclopedia of Toxicology 3rd edn (ed. Wexler, P.) 702–705 (Academic, 2014).

Takiishi, T., Fenero, C. I. M. & Câmara, N. O. S. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers 5, e1373208 (2017).

pubmed: 28956703 pmcid: 5788425 doi: 10.1080/21688370.2017.1373208

König, J. et al. Human intestinal barrier function in health and disease. Clin. Transl. Gastroenterol. 7, e196 (2016).

pubmed: 27763627 pmcid: 5288588 doi: 10.1038/ctg.2016.54

Willis, J. R. & Gabaldón, T. The human oral microbiome in health and disease: from sequences to ecosystems. Microorganisms 8, 308 (2020).

pubmed: 32102216 pmcid: 7074908 doi: 10.3390/microorganisms8020308

Baker, J. L., Mark Welch, J. L., Kauffman, K. M., McLean, J. S. & He, X. The oral microbiome: diversity, biogeography and human health. Nat. Rev. Microbiol. 22, 89–104 (2023). This review examines the biogeography of several oral niches at the species level, presenting not only bacteria but also microeukaryotes, archaea and viruses.

pubmed: 37700024 pmcid: 11084736 doi: 10.1038/s41579-023-00963-6

Diaz, P. I. & Dongari-Bagtzoglou, A. Critically appraising the significance of the oral mycobiome. J. Dent. Res. 100, 133–140 (2021).

pubmed: 32924741 doi: 10.1177/0022034520956975

Caselli, E. et al. Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. BMC Microbiol. 20, 120 (2020).

pubmed: 32423437 pmcid: 7236360 doi: 10.1186/s12866-020-01801-y

Lloyd-Price, J., Abu-Ali, G. & Huttenhower, C. The healthy human microbiome. Genome Med. 8, 51 (2016).

pubmed: 27122046 pmcid: 4848870 doi: 10.1186/s13073-016-0307-y

Donaldson, G. P., Lee, S. M. & Mazmanian, S. K. Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14, 20–32 (2016).

pubmed: 26499895 doi: 10.1038/nrmicro3552

Hillman, E. T., Lu, H., Yao, T. & Nakatsu, C. H. Microbial ecology along the gastrointestinal tract. Microbes Env. 32, 300–313 (2017).

doi: 10.1264/jsme2.ME17017

Assimakopoulos, S. F., Triantos, C., Maroulis, I. & Gogos, C. The role of the gut barrier function in health and disease. Gastroenterol. Res. Pract. 11, 261–263 (2018).

doi: 10.14740/gr1053w

Ding, T. & Schloss, P. D. Dynamics and associations of microbial community types across the human body. Nature 509, 357–360 (2014).

pubmed: 24739969 pmcid: 4139711 doi: 10.1038/nature13178

Schmidt, T. S. et al. Extensive transmission of microbes along the gastrointestinal tract. eLife 8, e42693 (2019). This study presents a metagenomic approach describing that the transmission to, and subsequent colonization of, the large intestine by oral microorganisms is common even among healthy individuals.

pubmed: 30747106 pmcid: 6424576 doi: 10.7554/eLife.42693

Kunath, B. J. et al. Alterations of oral microbiota and impact on the gut microbiome in type 1 diabetes mellitus revealed by integrated multi-omic analyses. Microbiome 10, 243 (2022). This paper confirms the transmission of oral microorganisms to the gut and shows strain-level activities using metatranscriptomics and metaproteomics.

pubmed: 36578059 pmcid: 9795701 doi: 10.1186/s40168-022-01435-4

Kamada, N., Chen, G. Y., Inohara, N. & Núñez, G. Control of pathogens and pathobionts by the gut microbiota. Nat. Immunol. 14, 685–690 (2013).

pubmed: 23778796 pmcid: 4083503 doi: 10.1038/ni.2608

Nakajima, M. et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. PLoS ONE 10, e0134234 (2015).

pubmed: 26218067 pmcid: 4517782 doi: 10.1371/journal.pone.0134234

Vaishnava, S., Behrendt, C. L., Ismail, A. S., Eckmann, L. & Hooper, L. V. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host–microbial interface. Proc. Natl Acad. Sci. USA 105, 20858–20863 (2008).

pubmed: 19075245 pmcid: 2603261 doi: 10.1073/pnas.0808723105

Atarashi, K. et al. Ectopic colonization of oral bacteria in the intestine drives T

pubmed: 29051379 pmcid: 5682622 doi: 10.1126/science.aan4526

Bao, J. et al. Periodontitis may induce gut microbiota dysbiosis via salivary microbiota. Int. J. Oral. Sci. 14, 32 (2022).

pubmed: 35732628 pmcid: 9217941 doi: 10.1038/s41368-022-00183-3

Tsukasaki, M. et al. Host defense against oral microbiota by bone-damaging T cells. Nat. Commun. 9, 701 (2018).

pubmed: 29453398 pmcid: 5816021 doi: 10.1038/s41467-018-03147-6

Abed, J. et al. Colon cancer-associated Fusobacterium nucleatum may originate from the oral cavity and reach colon tumors via the circulatory system. Front. Cell. Infect. Microbiol. 10, 400 (2020).

pubmed: 32850497 pmcid: 7426652 doi: 10.3389/fcimb.2020.00400

Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016).

pubmed: 26657899 doi: 10.1136/gutjnl-2015-310376

Guo, W. et al. Depletion of gut microbiota impairs gut barrier function and antiviral immune defense in the liver. Front. Immunol. 12, 636803 (2021).

pubmed: 33841420 pmcid: 8027085 doi: 10.3389/fimmu.2021.636803

Hunt, R. H. et al. The stomach in health and disease. Gut 64, 1650–1668 (2015).

pubmed: 26342014 doi: 10.1136/gutjnl-2014-307595

Sato, K. et al. Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system. Sci. Rep. 7, 6955 (2017).

pubmed: 28761156 pmcid: 5537233 doi: 10.1038/s41598-017-07196-7

Martínez-García, M. & Hernández-Lemus, E. Periodontal inflammation and systemic diseases: an overview. Front. Physiol. 12, 709438 (2021).

pubmed: 34776994 pmcid: 8578868 doi: 10.3389/fphys.2021.709438

Ramadan, D. E., Hariyani, N., Indrawati, R., Ridwan, R. D. & Diyatri, I. Cytokines and chemokines in periodontitis. Eur. J. Dent. 14, 483–495 (2020).

pubmed: 32575137 pmcid: 7440949 doi: 10.1055/s-0040-1712718

Könönen, E. & Gursoy, U. K. Oral prevotella species and their connection to events of clinical relevance in gastrointestinal and respiratory tracts. Front. Microbiol. 12, 798763 (2021).

pubmed: 35069501 doi: 10.3389/fmicb.2021.798763

Salter, S. J. et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 12, 87 (2014).

pubmed: 25387460 pmcid: 4228153 doi: 10.1186/s12915-014-0087-z

Heintz-Buschart, A. et al. Small RNA profiling of low biomass samples: identification and removal of contaminants. BMC Biol. 16, 52 (2018).

pubmed: 29759067 pmcid: 5952572 doi: 10.1186/s12915-018-0522-7

Van Rossum, T., Ferretti, P., Maistrenko, O. M. & Bork, P. Diversity within species: interpreting strains in microbiomes. Nat. Rev. Microbiol. 18, 491–506 (2020). This paper discusses high-resolution strain and subspecies analyses in metagenomic data and how within-species variation can be studied and stratified directly within microbial communities.

pubmed: 32499497 pmcid: 7610499 doi: 10.1038/s41579-020-0368-1

Sedghi, L. M., Bacino, M. & Kapila, Y. L. Periodontal disease: the good, the bad, and the unknown. Front. Cell. Infect. Microbiol. 11, 766944 (2021).

pubmed: 34950607 pmcid: 8688827 doi: 10.3389/fcimb.2021.766944

Curtis, M. A., Diaz, P. I. & Van Dyke, T. E. The role of the microbiota in periodontal disease. Periodontol 2000 83, 14–25 (2020).

pubmed: 32385883 doi: 10.1111/prd.12296

Kinane, D. F., Stathopoulou, P. G. & Papapanou, P. N. Periodontal diseases. Nat. Rev. Dis. Prim. 3, 17038 (2017).

pubmed: 28805207 doi: 10.1038/nrdp.2017.38

Tuominen, H. & Rautava, J. Oral Microbiota and cancer development. Pathobiology 88, 116–126 (2021).

pubmed: 33176328 doi: 10.1159/000510979

Strauss, J. et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis. 17, 1971–1978 (2011).

pubmed: 21830275 doi: 10.1002/ibd.21606

Carrillo-de-Albornoz, A., Figuero, E., Herrera, D. & Bascones-Martínez, A. Gingival changes during pregnancy: II. Influence of hormonal variations on the subgingival biofilm. J. Clin. Periodontol. 37, 230–240 (2010).

pubmed: 20088983 doi: 10.1111/j.1600-051X.2009.01514.x

Abusleme, L. et al. The subgingival microbiome in health and periodontitis and its relationship with community biomass and inflammation. ISME J. 7, 1016–1025 (2013).

pubmed: 23303375 pmcid: 3635234 doi: 10.1038/ismej.2012.174

Kitamoto, S., Nagao-Kitamoto, H., Hein, R., Schmidt, T. M. & Kamada, N. The bacterial connection between the oral cavity and the gut diseases. J. Dent. Res. 99, 1021–1029 (2020).

pubmed: 32464078 pmcid: 7375741 doi: 10.1177/0022034520924633

Franzosa, E. A. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 4, 293–305 (2019). This study integrates metagenomic analyses with in-depth metabolomic measurements and highlights possible mechanistic relationships that are perturbed in IBD.

pubmed: 30531976 doi: 10.1038/s41564-018-0306-4

Schirmer, M. et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat. Microbiol. 3, 337–346 (2018). This study integrates metagenomic analysis with metatranscriptomic measurements, identifying keystone species in terms of activities and providing finer insight into the role of the microbiome in IBD.

pubmed: 29311644 pmcid: 6131705 doi: 10.1038/s41564-017-0089-z

Vandeputte, D. et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature 551, 507–511 (2017). This paper presents a method that can provide information about the extent or directionality of changes in taxa abundance or metabolic potential by bypassing compositionality effects in the reconstruction of gut microbiota interaction networks.

pubmed: 29143816 doi: 10.1038/nature24460

Ohkusa, T. et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J. Gastroenterol. Hepatol. 17, 849–853 (2002).

pubmed: 12164960 doi: 10.1046/j.1440-1746.2002.02834.x

Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014).

pubmed: 24629344 pmcid: 4059512 doi: 10.1016/j.chom.2014.02.005

Kirk, K. F., Nielsen, H. L., Thorlacius-Ussing, O. & Nielsen, H. Optimized cultivation of Campylobacter concisus from gut mucosal biopsies in inflammatory bowel disease. Gut Pathog. 8, 27 (2016).

pubmed: 27252786 pmcid: 4888738 doi: 10.1186/s13099-016-0111-7

Huh, J.-W. & Roh, T.-Y. Opportunistic detection of Fusobacterium nucleatum as a marker for the early gut microbial dysbiosis. BMC Microbiol. 20, 208 (2020).

pubmed: 32660414 pmcid: 7359021 doi: 10.1186/s12866-020-01887-4

Lee, Y.-C. et al. The periodontopathic pathogen, Porphyromonas gingivalis, involves a gut inflammatory response and exacerbates inflammatory bowel disease. Pathogens 11, 84 (2022).

pubmed: 35056032 pmcid: 8779656 doi: 10.3390/pathogens11010084

Said, H. S. et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res. 21, 15–25 (2014).

pubmed: 24013298 doi: 10.1093/dnares/dst037

Xun, Z., Zhang, Q., Xu, T., Chen, N. & Chen, F. Dysbiosis and ecotypes of the salivary microbiome associated with inflammatory bowel diseases and the assistance in diagnosis of diseases using oral bacterial profiles. Front. Microbiol. 9, 1136 (2018).

pubmed: 29899737 pmcid: 5988890 doi: 10.3389/fmicb.2018.01136

Kelsen, J. et al. Alterations of the subgingival microbiota in pediatric Crohn’s disease studied longitudinally in discovery and validation cohorts. Inflamm. Bowel Dis. 21, 2797–2805 (2015).

pubmed: 26288001 doi: 10.1097/MIB.0000000000000557

Elzayat, H. et al. Deciphering salivary microbiome signature in Crohn’s disease patients with different factors contributing to dysbiosis. Sci. Rep. 13, 19198 (2023).

pubmed: 37932491 pmcid: 10628307 doi: 10.1038/s41598-023-46714-8

Abdelbary, M. M. H. et al. The oral–gut axis: salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease. Front. Cell. Infect. Microbiol. 12, 1010853 (2022).

pubmed: 36275026 pmcid: 9585322 doi: 10.3389/fcimb.2022.1010853

Zhang, T. et al. Dynamics of the salivary microbiome during different phases of Crohn’s disease. Front. Cell. Infect. Microbiol. 10, 544704 (2020).

pubmed: 33123492 pmcid: 7574453 doi: 10.3389/fcimb.2020.544704

Madsen, G. R. et al. The impact of periodontitis on inflammatory bowel disease activity. Inflamm. Bowel Dis. 29, 396–404 (2023).

pubmed: 35552410 doi: 10.1093/ibd/izac090

Koutsochristou, V. et al. Dental caries and periodontal disease in children and adolescents with inflammatory bowel disease: a case–control study. Inflamm. Bowel Dis. 21, 1839–1846 (2015).

pubmed: 25985243 doi: 10.1097/MIB.0000000000000452

She, Y.-Y. et al. Periodontitis and inflammatory bowel disease: a meta-analysis. BMC Oral. Health 20, 67 (2020).

pubmed: 32164696 pmcid: 7069057 doi: 10.1186/s12903-020-1053-5

Baima, G. et al. Periodontitis prevalence and severity in inflammatory bowel disease: a case–control study. J. Periodontol. 94, 313–322 (2023).

pubmed: 36111636 doi: 10.1002/JPER.22-0322

Papageorgiou, S. N. et al. Inflammatory bowel disease and oral health: systematic review and a meta-analysis. J. Clin. Periodontol. 44, 382–393 (2017).

pubmed: 28117909 doi: 10.1111/jcpe.12698

Zhou, P., Li, X., Huang, I.-H. & Qi, F. Veillonella catalase protects the growth of Fusobacterium nucleatum in microaerophilic and Streptococcus gordonii-resident environments. Appl. Environ. Microbiol. 83, e01079–e01117 (2017).

pubmed: 28778894 pmcid: 5601340 doi: 10.1128/AEM.01079-17

Lenartova, M. et al. The oral microbiome in periodontal health. Front. Cell. Infect. Microbiol. 11, 629723 (2021).

pubmed: 33828997 pmcid: 8019927 doi: 10.3389/fcimb.2021.629723

Carrion, J. et al. Microbial carriage state of peripheral blood dendritic cells (DCs) in chronic periodontitis influences DC differentiation, atherogenic potential. J. Immunol. 189, 3178–3187 (2012).

pubmed: 22891282 doi: 10.4049/jimmunol.1201053

Xue, Y. et al. Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages. Cell Death Dis. 9, 355 (2018).

pubmed: 29500439 pmcid: 5834448 doi: 10.1038/s41419-018-0389-0

Chen, Y. et al. Fusobacterium nucleatum facilitates ulcerative colitis through activating IL-17F signaling to NF-κB via the upregulation of CARD3 expression. J. Pathol. 250, 170–182 (2020).

pubmed: 31610014 doi: 10.1002/path.5358

Tang, W. et al. Impairment of intestinal barrier function induced by early weaning via autophagy and apoptosis associated with gut microbiome and metabolites. Front. Immunol. 12, 804870 (2021).

pubmed: 34975919 pmcid: 8714829 doi: 10.3389/fimmu.2021.804870

Feng, Y.-K. et al. Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice. J. Neuroinflammation 17, 347 (2020).

pubmed: 33213462 pmcid: 7677837 doi: 10.1186/s12974-020-02027-5

van der Post, S. et al. Site-specific O-glycosylation on the MUC2 mucin protein inhibits cleavage by the Porphyromonas gingivalis secreted cysteine protease (RgpB). J. Biol. Chem. 288, 14636–14646 (2013).

pubmed: 23546879 pmcid: 3656315 doi: 10.1074/jbc.M113.459479

Kitamoto, S. et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell 182, 447–462.e14 (2020). This study shows that oral bacteria-specific T

pubmed: 32758418 pmcid: 7414097 doi: 10.1016/j.cell.2020.05.048

El Tekle, G. & Garrett, W. S. Bacteria in cancer initiation, promotion and progression. Nat. Rev. Cancer 23, 600–618 (2023).

pubmed: 37400581 doi: 10.1038/s41568-023-00594-2

Ternes, D. et al. Microbiome in colorectal cancer: how to get from meta-omics to mechanism? Trends Microbiol. 28, 401–423 (2020). This review presents new experimental approaches for gaining ecosystem-level mechanistic understanding of the gut microbiome’s role in cancer pathogenesis.

pubmed: 32298617 doi: 10.1016/j.tim.2020.01.001

Simpson, R. C., Shanahan, E. R., Scolyer, R. A. & Long, G. V. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 20, 697–715 (2023). This review discusses the mechanisms by which the microbiota modulates antitumour immunity.

pubmed: 37488231 doi: 10.1038/s41571-023-00803-9

Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).

pubmed: 29097493 doi: 10.1126/science.aan4236

Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).

pubmed: 29302014 pmcid: 6707353 doi: 10.1126/science.aao3290

Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

pubmed: 29097494 doi: 10.1126/science.aan3706

Flemer, B. et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut 67, 1454–1463 (2018).

pubmed: 28988196 doi: 10.1136/gutjnl-2017-314814

Li, S. et al. Prognostic impact of oral microbiome on survival of malignancies: a systematic review and meta-analysis. Syst. Rev. 13, 41 (2024).

pubmed: 38273347 pmcid: 10809532 doi: 10.1186/s13643-023-02419-7

Lee, W.-H. et al. Bacterial alterations in salivary microbiota and their association in oral cancer. Sci. Rep. 7, 16540 (2017).

pubmed: 29184122 pmcid: 5705712 doi: 10.1038/s41598-017-16418-x

Pushalkar, S. et al. Microbial diversity in saliva of oral squamous cell carcinoma. FEMS Immunol. Med. Microbiol. 61, 269–277 (2011).

pubmed: 21205002 pmcid: 3078631 doi: 10.1111/j.1574-695X.2010.00773.x

Schmidt, B. L. et al. Changes in abundance of oral microbiota associated with oral cancer. PLoS ONE 9, e98741 (2014).

pubmed: 24887397 pmcid: 4041887 doi: 10.1371/journal.pone.0098741

Torres, P. J. et al. Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ 3, e1373 (2015).

pubmed: 26587342 pmcid: 4647550 doi: 10.7717/peerj.1373

Peters, B. A. et al. Oral microbiome composition reflects prospective risk for esophageal cancers. Cancer Res. 77, 6777–6787 (2017).

pubmed: 29196415 pmcid: 5726431 doi: 10.1158/0008-5472.CAN-17-1296

Fan, X. et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case–control study. Gut 67, 120–127 (2018).

pubmed: 27742762 doi: 10.1136/gutjnl-2016-312580

Conde-Pérez, K. et al. Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma. Mol. Oncol. 18, 1143–1173 (2023).

pubmed: 37558206 pmcid: 11076991 doi: 10.1002/1878-0261.13506

Knippel, R. J., Drewes, J. L. & Sears, C. L. The cancer microbiome: recent highlights and knowledge gaps. Cancer Discov. 11, 2378–2395 (2021).

pubmed: 34400408 pmcid: 8487941 doi: 10.1158/2159-8290.CD-21-0324

Chen, M.-F., Lu, M.-S., Hsieh, C.-C. & Chen, W.-C. Porphyromonas gingivalis promotes tumor progression in esophageal squamous cell carcinoma. Cell. Oncol. 44, 373–384 (2021).

doi: 10.1007/s13402-020-00573-x

Wen, L. et al. Porphyromonas gingivalis promotes oral squamous cell carcinoma progression in an immune microenvironment. J. Dent. Res. 99, 666–675 (2020).

pubmed: 32298192 doi: 10.1177/0022034520909312

Michaud, D. S. et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 62, 1764–1770 (2013).

pubmed: 22990306 doi: 10.1136/gutjnl-2012-303006

Saba, E. et al. Oral bacteria accelerate pancreatic cancer development in mice. Gut 73, 770–786 (2024).

pubmed: 38233197 doi: 10.1136/gutjnl-2023-330941

Sztukowska, M. N. et al. Porphyromonas gingivalis initiates a mesenchymal-like transition through ZEB1 in gingival epithelial cells. Cell. Microbiol. 18, 844–858 (2016).

pubmed: 26639759 pmcid: 5135094 doi: 10.1111/cmi.12554

Haerinck, J., Goossens, S. & Berx, G. The epithelial–mesenchymal plasticity landscape: principles of design and mechanisms of regulation. Nat. Rev. Genet. 24, 590–609 (2023).

pubmed: 37169858 doi: 10.1038/s41576-023-00601-0

Ternes, D. et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat. Metab. 4, 458–475 (2022). This study describes molecular signatures linking CRC phenotypes with Fusobacterium spp. abundance and identifies formate as a gut-derived oncometabolite relevant for CRC progression.

pubmed: 35437333 pmcid: 9046088 doi: 10.1038/s42255-022-00558-0

Komiya, Y. et al. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut 68, 1335–1337 (2019).

pubmed: 29934439 doi: 10.1136/gutjnl-2018-316661

Nosho, K. et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J. Gastroenterol. 22, 557–566 (2016).

pubmed: 26811607 pmcid: 4716059 doi: 10.3748/wjg.v22.i2.557

Tahara, T. et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 74, 1311–1318 (2014).

pubmed: 24385213 pmcid: 4396185 doi: 10.1158/0008-5472.CAN-13-1865

Kim, H. S. et al. Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers. Front. Cell. Infect. Microbiol. 13, 1101291 (2023).

pubmed: 36960042 pmcid: 10028079 doi: 10.3389/fcimb.2023.1101291

Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344–355 (2015).

pubmed: 25680274 pmcid: 4361732 doi: 10.1016/j.immuni.2015.01.010

Kosuke, M. et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1, 653–661 (2015).

doi: 10.1001/jamaoncol.2015.1377

Serna, G. et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann. Oncol. 31, 1366–1375 (2020).

pubmed: 32569727 doi: 10.1016/j.annonc.2020.06.003

Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 20, e47638 (2019).

pubmed: 30833345 pmcid: 6446206 doi: 10.15252/embr.201847638

Li, X. et al. Fusobacterium nucleatum promotes the progression of colorectal cancer through Cdk5-activated Wnt/β-catenin signaling. Front. Microbiol. 11, 545251 (2020).

pubmed: 33488528 doi: 10.3389/fmicb.2020.545251

Coppenhagen-Glazer, S. et al. Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. Infect. Immun. 83, 1104–1113 (2015).

pubmed: 25561710 pmcid: 4333458 doi: 10.1128/IAI.02838-14

Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563.e16 (2017).

pubmed: 28753429 pmcid: 5767127 doi: 10.1016/j.cell.2017.07.008

Liu, Y. et al. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br. J. Cancer 124, 963–974 (2021).

pubmed: 33299132 doi: 10.1038/s41416-020-01198-5

Jiang, S.-S. et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31, 781–797.e9 (2023).

pubmed: 37130518 doi: 10.1016/j.chom.2023.04.010

Zepeda-Rivera, M. et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature 628, 424–432 (2024).

pubmed: 38509359 pmcid: 11006615 doi: 10.1038/s41586-024-07182-w

Higashi, D. L. et al. Who is in the driver’s seat? Parvimonas micra: an understudied pathobiont at the crossroads of dysbiotic disease and cancer. Environ. Microbiol. Rep. 15, 254–264 (2023).

pubmed: 36999244 pmcid: 10316381 doi: 10.1111/1758-2229.13153

Bergsten, E. et al. Parvimonas micra, an oral pathobiont associated with colorectal cancer, epigenetically reprograms human colonocytes. Gut Microbes 15, 2265138 (2023).

pubmed: 37842920 pmcid: 10580862 doi: 10.1080/19490976.2023.2265138

Zhao, L. et al. Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients. Oncogene 41, 4200–4210 (2022).

pubmed: 35882981 pmcid: 9439953 doi: 10.1038/s41388-022-02395-7

Xu, J. et al. Alteration of the abundance of Parvimonas micra in the gut along the adenoma–carcinoma sequence. Oncol. Lett. 20, 106 (2020).

pubmed: 32831925 pmcid: 7439112 doi: 10.3892/ol.2020.11967

Genco, R. J. et al. The subgingival microbiome relationship to periodontal disease in older women. J. Dent. Res. 98, 975–984 (2019).

pubmed: 31329044 pmcid: 6651762 doi: 10.1177/0022034519860449

Marchesan, J. et al. TLR4, NOD1 and NOD2 mediate immune recognition of putative newly identified periodontal pathogens. Mol. Oral. Microbiol. 31, 243–258 (2016).

pubmed: 26177212 doi: 10.1111/omi.12116

Sakanaka, A. et al. Fusobacterium nucleatum metabolically integrates commensals and pathogens in oral biofilms. mSystems 7, e0017022 (2022).

pubmed: 35852319 doi: 10.1128/msystems.00170-22

Zheng, D.-W. et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat. Biomed. Eng. 3, 717–728 (2019).

pubmed: 31332342 doi: 10.1038/s41551-019-0423-2

Zhang, Y. Epidemiology of esophageal cancer. World J. Gastroenterol. 19, 5598–5606 (2013).

pubmed: 24039351 pmcid: 3769895 doi: 10.3748/wjg.v19.i34.5598

Yano, Y., Etemadi, A. & Abnet, C. C. Microbiome and cancers of the esophagus: a review. Microorganisms 9, 1764 (2021).

pubmed: 34442842 pmcid: 8398938 doi: 10.3390/microorganisms9081764

Chen, X. et al. Oral microbiota and risk for esophageal squamous cell carcinoma in a high-risk area of China. PLoS ONE 10, e0143603 (2015).

pubmed: 26641451 pmcid: 4671675 doi: 10.1371/journal.pone.0143603

Zhao, Q. et al. Alterations of oral microbiota in chinese patients with esophageal cancer. Front. Cell. Infect. Microbiol. 10, 541144 (2020).

pubmed: 33194789 pmcid: 7609410 doi: 10.3389/fcimb.2020.541144

Snider, E. J. et al. Barrett’s esophagus is associated with a distinct oral microbiome. Clin. Transl. Gastroenterol. 9, 135 (2018).

pubmed: 29491399 pmcid: 5862155 doi: 10.1038/s41424-018-0005-8

Shao, D. et al. Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China. Cancer 125, 3993–4002 (2019).

pubmed: 31355925 doi: 10.1002/cncr.32403

Li, D. et al. Characterization of the esophageal microbiota and prediction of the metabolic pathways involved in esophageal cancer. Front. Cell. Infect. Microbiol. 10, 268 (2020).

pubmed: 32676460 pmcid: 7333312 doi: 10.3389/fcimb.2020.00268

Yamamura, K. et al. Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin. Cancer Res. 22, 5574–5581 (2016).

pubmed: 27769987 doi: 10.1158/1078-0432.CCR-16-1786

Gao, S. et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect. Agent. Cancer 11, 3 (2016).

pubmed: 26788120 pmcid: 4717526 doi: 10.1186/s13027-016-0049-x

Farrell, J. J. et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582–588 (2012).

pubmed: 21994333 doi: 10.1136/gutjnl-2011-300784

Stingu, C.-S., Eschrich, K., Rodloff, A. C., Schaumann, R. & Jentsch, H. Periodontitis is associated with a loss of colonization by Streptococcus sanguinis. J. Med. Microbiol. 57, 495–499 (2008).

pubmed: 18349371 doi: 10.1099/jmm.0.47649-0

Teughels, W. et al. Bacteria interfere with A. actinomycetemcomitans colonization. J. Dent. Res. 86, 611–617 (2007).

pubmed: 17586706 doi: 10.1177/154405910708600706

Andrukhov, O. et al. Serum cytokine levels in periodontitis patients in relation to the bacterial load. J. Periodontol. 82, 885–892 (2011).

pubmed: 21138356 doi: 10.1902/jop.2010.100425

Gemmell, E., Marshall, R. I. & Seymour, G. J. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontol 2000 14, 112–143 (1997).

pubmed: 9567968 doi: 10.1111/j.1600-0757.1997.tb00194.x

Nauseef, W. M. & Borregaard, N. Neutrophils at work. Nat. Immunol. 15, 602–611 (2014).

pubmed: 24940954 doi: 10.1038/ni.2921

Fine, N. et al. Primed PMNs in healthy mouse and human circulation are first responders during acute inflammation. Blood Adv. 3, 1622–1637 (2019).

pubmed: 31138591 pmcid: 6538871 doi: 10.1182/bloodadvances.2018030585

Fine, N. et al. Periodontal inflammation primes the systemic innate immune response. J. Dent. Res. 100, 318–325 (2021).

pubmed: 33078669 doi: 10.1177/0022034520963710

Fine, N. et al. Distinct oral neutrophil subsets define health and periodontal disease states. J. Dent. Res. 95, 931–938 (2016).

pubmed: 27270666 doi: 10.1177/0022034516645564

Hajishengallis, G., Chavakis, T., Hajishengallis, E. & Lambris, J. D. Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis. J. Leukoc. Biol. 98, 539–548 (2015).

pubmed: 25548253 doi: 10.1189/jlb.3VMR1014-468R

Rossol, M. et al. LPS-induced cytokine production in human monocytes and macrophages. Crit. Rev. Immunol. 31, 379–446 (2011).

pubmed: 22142165 doi: 10.1615/CritRevImmunol.v31.i5.20

Zijnge, V., Kieselbach, T. & Oscarsson, J. Proteomics of protein secretion by Aggregatibacter actinomycetemcomitans. PLoS ONE 7, e41662 (2012).

pubmed: 22848560 pmcid: 3405016 doi: 10.1371/journal.pone.0041662

Konig, M. F. et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci. Transl. Med. 8, 369ra176 (2016).

pubmed: 27974664 pmcid: 5384717 doi: 10.1126/scitranslmed.aaj1921

Stobernack, T. et al. Extracellular proteome and citrullinome of the oral pathogen Porphyromonas gingivalis. J. Proteome Res. 15, 4532–4543 (2016).

pubmed: 27712078 doi: 10.1021/acs.jproteome.6b00634

Farrugia, C. et al. Mechanisms of vascular damage by systemic dissemination of the oral pathogen Porphyromonas gingivalis. FEBS J. 288, 1479–1495 (2021).

pubmed: 32681704 doi: 10.1111/febs.15486

Gimbrone, M. A. Jr & García-Cardeña, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res. 118, 620–636 (2016).

pubmed: 26892962 pmcid: 4762052 doi: 10.1161/CIRCRESAHA.115.306301

Bajaj, J. S. et al. Periodontal therapy favorably modulates the oral–gut–hepatic axis in cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 315, G824–G837 (2018).

pubmed: 30118351 pmcid: 6293251 doi: 10.1152/ajpgi.00230.2018

Schenkein, H. A., Papapanou, P. N., Genco, R. & Sanz, M. Mechanisms underlying the association between periodontitis and atherosclerotic disease. Periodontol 2000 83, 90–106 (2020).

pubmed: 32385879 doi: 10.1111/prd.12304

D’Aiuto, F., Orlandi, M. & Gunsolley, J. C. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J. Clin. Periodontol. 40, S85–S105 (2013).

pubmed: 23627337

Sanz, M. et al. Periodontitis and cardiovascular diseases: consensus report. J. Clin. Periodontol. 47, 268–288 (2020).

pubmed: 32011025 pmcid: 7027895 doi: 10.1111/jcpe.13189

Teeuw, W. J., Gerdes, V. E. A. & Loos, B. G. Effect of periodontal treatment on glycemic control of diabetic patients: a systematic review and meta-analysis. Diabetes Care 33, 421–427 (2010).

pubmed: 20103557 pmcid: 2809296 doi: 10.2337/dc09-1378

Teshome, A. & Yitayeh, A. The effect of periodontal therapy on glycemic control and fasting plasma glucose level in type 2 diabetic patients: systematic review and meta-analysis. BMC Oral. Health 17, 31 (2016).

pubmed: 27473177 pmcid: 4967318 doi: 10.1186/s12903-016-0249-1

Tanwar, H. et al. Unraveling the link between periodontitis and inflammatory bowel disease: challenges and outlook. Preprint at arXiv https://doi.org/10.48550/arXiv.2308.10907 (2023).

Zhang, Y. et al. The association between periodontitis and inflammatory bowel disease: a systematic review and meta-analysis. Biomed. Res. Int. 2021, 6692420 (2021).

pubmed: 33778080 pmcid: 7981176

Pietropaoli, D. et al. Occurrence of spontaneous periodontal disease in the SAMP1/YitFc murine model of Crohn disease. J. Periodontol. 85, 1799–1805 (2014).

pubmed: 25019175 pmcid: 4460836 doi: 10.1902/jop.2014.140316

Teles, F., Wang, Y., Hajishengallis, G., Hasturk, H. & Marchesan, J. T. Impact of systemic factors in shaping the periodontal microbiome. Periodontol 2000 85, 126–160 (2021).

pubmed: 33226693 doi: 10.1111/prd.12356

Genco, R. J. & Sanz, M. Clinical and public health implications of periodontal and systemic diseases: an overview. Periodontol 2000 83, 7–13 (2020).

pubmed: 32385880 doi: 10.1111/prd.12344

Xiao, E. et al. Diabetes enhances IL-17 expression and alters the oral microbiome to increase its pathogenicity. Cell Host Microbe 22, 120–128.e4 (2017).

pubmed: 28704648 pmcid: 5701758 doi: 10.1016/j.chom.2017.06.014

D’Aiuto, F. et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. 6, 954–965 (2018). This study shows favourable effects of local periodontal treatment on systemic inflammatory markers and glycaemic control in patients with type 2 diabetes mellitus.

pubmed: 30472992 doi: 10.1016/S2213-8587(18)30038-X

Duarte, P. M. et al. Local levels of inflammatory mediators in uncontrolled type 2 diabetic subjects with chronic periodontitis. J. Clin. Periodontol. 41, 11–18 (2014).

pubmed: 24206042 doi: 10.1111/jcpe.12179

Lalla, E., Lamster, I. B., Stern, D. M. & Schmidt, A. M. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. Ann. Periodontol. 6, 113–118 (2001).

pubmed: 11887453 doi: 10.1902/annals.2001.6.1.113

Sato, K. et al. Obesity-related gut microbiota aggravates alveolar bone destruction in experimental periodontitis through elevation of uric acid. MBio 12, e0077121 (2021).

pubmed: 34061595 doi: 10.1128/mBio.00771-21

Kato, T. et al. Oral administration of Porphyromonas gingivalis alters the gut microbiome and serum metabolome. mSphere 3, https://doi.org/10.1128/msphere.00460-18 (2018).

Blasco-Baque, V. et al. Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut 66, 872–885 (2017).

pubmed: 26838600 doi: 10.1136/gutjnl-2015-309897

Goettel, J. A. et al. Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood 125, 3886–3895 (2015).

pubmed: 25833964 pmcid: 4473116 doi: 10.1182/blood-2014-12-618363

Wahl, A. et al. A germ-free humanized mouse model shows the contribution of resident microbiota to human-specific pathogen infection. Nat. Biotechnol. 42, 905–915 (2023).

pubmed: 37563299 pmcid: 11073568 doi: 10.1038/s41587-023-01906-5

Bai, L., Chen, B.-Y., Liu, Y., Zhang, W.-C. & Duan, S.-Z. A mouse periodontitis model with humanized oral bacterial community. Front. Cell. Infect. Microbiol. 12, 842845 (2022).

pubmed: 35273925 pmcid: 8902145 doi: 10.3389/fcimb.2022.842845

Li, B. et al. Oral bacteria colonize and compete with gut microbiota in gnotobiotic mice. Int. J. Oral. Sci. 11, 10 (2019).

pubmed: 30833566 pmcid: 6399334 doi: 10.1038/s41368-018-0043-9

de Nies, L. et al. Altered infective competence of the human gut microbiome in COVID-19. Microbiome 11, 46 (2023).

pubmed: 36894986 pmcid: 9995755 doi: 10.1186/s40168-023-01472-7

Segata, N. et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 13, R42 (2012).

pubmed: 22698087 pmcid: 3446314 doi: 10.1186/gb-2012-13-6-r42

van ’t Hof, W., Veerman, E. C. I., Nieuw Amerongen, A. V. & Ligtenberg, A. J. M. Antimicrobial defense systems in saliva. Monogr. Oral. Sci. 24, 40–51 (2014).

pubmed: 24862593 doi: 10.1159/000358783

Amerongen, A. V. N. & Veerman, E. C. I. Saliva—the defender of the oral cavity. Oral. Dis. 8, 12–22 (2002).

pubmed: 11936451 doi: 10.1034/j.1601-0825.2002.1o816.x

Lynge Pedersen, A. M. & Belstrøm, D. The role of natural salivary defences in maintaining a healthy oral microbiota. J. Dent. 80, S3–S12 (2019).

pubmed: 30696553 doi: 10.1016/j.jdent.2018.08.010

Ahuja, M. et al. Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity. Cell Metab. 25, 635–646 (2017).

pubmed: 28273482 pmcid: 5345693 doi: 10.1016/j.cmet.2017.02.007

Martinsen, T. C., Bergh, K. & Waldum, H. L. Gastric juice: a barrier against infectious diseases. Basic. Clin. Pharmacol. Toxicol. 96, 94–102 (2005).

pubmed: 15679471 doi: 10.1111/j.1742-7843.2005.pto960202.x

Tennant, S. M. et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect. Immun. 76, 639–645 (2008).

pubmed: 18025100 doi: 10.1128/IAI.01138-07

Bischoff, S. C. et al. Intestinal permeability—a new target for disease prevention and therapy. BMC Gastroenterol. 14, 189 (2014).

pubmed: 25407511 pmcid: 4253991 doi: 10.1186/s12876-014-0189-7

Odenwald, M. A. & Turner, J. R. The intestinal epithelial barrier: a therapeutic target? Nat. Rev. Gastroenterol. Hepatol. 14, 9–21 (2017).

pubmed: 27848962 doi: 10.1038/nrgastro.2016.169

Pott, J. & Hornef, M. Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep. 13, 684–698 (2012).

pubmed: 22801555 pmcid: 3410395 doi: 10.1038/embor.2012.96

Dillon, A. & Lo, D. D. M cells: intelligent engineering of mucosal immune surveillance. Front. Immunol. 10, 1499 (2019).

pubmed: 31312204 pmcid: 6614372 doi: 10.3389/fimmu.2019.01499

Huus, K. E., Petersen, C. & Finlay, B. B. Diversity and dynamism of IgA–microbiota interactions. Nat. Rev. Immunol. 21, 514–525 (2021).

pubmed: 33568782 doi: 10.1038/s41577-021-00506-1

Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13, 790–801 (2013).

pubmed: 24096337 pmcid: 4194195 doi: 10.1038/nri3535

Pickard, J. M., Zeng, M. Y., Caruso, R. & Núñez, G. Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. Immunol. Rev. 279, 70–89 (2017).

pubmed: 28856738 pmcid: 5657496 doi: 10.1111/imr.12567

Parker, C. T., Tindall, B. J. & Garrity, G. M. (eds) International code of nomenclature of prokaryotes. Int. J. Syst. Evol. Microbiol. 69, S1–S111 (2019).

doi: 10.1099/ijsem.0.000778

Tikhonov, M., Leach, R. W. & Wingreen, N. S. Interpreting 16S metagenomic data without clustering to achieve sub-OTU resolution. ISME J. 9, 68–80 (2015).

pubmed: 25012900 doi: 10.1038/ismej.2014.117

Amir, A. et al. Deblur rapidly resolves single-nucleotide community sequence patterns. mSystems 2, e00191–e00216 (2017).

pubmed: 28289731 pmcid: 5340863 doi: 10.1128/mSystems.00191-16

Johnson, J. S. et al. Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis. Nat. Commun. 10, 5029 (2019).

pubmed: 31695033 pmcid: 6834636 doi: 10.1038/s41467-019-13036-1

Alneberg, J. et al. Genomes from uncultivated prokaryotes: a comparison of metagenome-assembled and single-amplified genomes. Microbiome 6, 173 (2018).

pubmed: 30266101 pmcid: 6162917 doi: 10.1186/s40168-018-0550-0

Zolfo, M., Tett, A., Jousson, O., Donati, C. & Segata, N. MetaMLST: multi-locus strain-level bacterial typing from metagenomic samples. Nucleic Acids Res. 45, e7 (2017).

pubmed: 27651451 doi: 10.1093/nar/gkw837

Smillie, C. S. et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23, 229–240.e5 (2018).

pubmed: 29447696 pmcid: 8318347 doi: 10.1016/j.chom.2018.01.003

Truong, D. T., Tett, A., Pasolli, E., Huttenhower, C. & Segata, N. Microbial strain-level population structure and genetic diversity from metagenomes. Genome Res. 27, 626–638 (2017).

pubmed: 28167665 pmcid: 5378180 doi: 10.1101/gr.216242.116

Nayfach, S., Rodriguez-Mueller, B., Garud, N. & Pollard, K. S. An integrated metagenomics pipeline for strain profiling reveals novel patterns of bacterial transmission and biogeography. Genome Res. 26, 1612–1625 (2016).

pubmed: 27803195 pmcid: 5088602 doi: 10.1101/gr.201863.115

Albanese, D. & Donati, C. Strain profiling and epidemiology of bacterial species from metagenomic sequencing. Nat. Commun. 8, 2260 (2017).

pubmed: 29273717 pmcid: 5741664 doi: 10.1038/s41467-017-02209-5

Shaiber, A. & Eren, A. M. Composite metagenome-assembled genomes reduce the quality of public genome repositories. mBio 10, e00725–e00819 (2019).

pubmed: 31164461 pmcid: 6550520 doi: 10.1128/mBio.00725-19

Lo Curto, A. et al. Survival of probiotic lactobacilli in the upper gastrointestinal tract using an in vitro gastric model of digestion. Food Microbiol. 28, 1359–1366 (2011).

pubmed: 21839386 doi: 10.1016/j.fm.2011.06.007

Minekus, M. et al. A standardised static in vitro digestion method suitable for food—an international consensus. Food Funct. 5, 1113–1124 (2014).

pubmed: 24803111 doi: 10.1039/C3FO60702J

Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405.e21 (2018).

pubmed: 30193112 doi: 10.1016/j.cell.2018.08.041

Van den Abbeele, P. et al. Microbial community development in a dynamic gut model is reproducible, colon region specific, and selective for Bacteroidetes and Clostridium cluster IX. Appl. Environ. Microbiol. 76, 5237–5246 (2010).

pubmed: 20562281 pmcid: 2916472 doi: 10.1128/AEM.00759-10

Van den Abbeele, P. et al. Incorporating a mucosal environment in a dynamic gut model results in a more representative colonization by lactobacilli. Microb. Biotechnol. 5, 106–115 (2012).

pubmed: 21989255 doi: 10.1111/j.1751-7915.2011.00308.x

Minekus, M., Marteau, P., Havenaar, R. & Veld, J. H. J. H. I. A multicompartmental dynamic computer-controlled model simulating the stomach and small intestine. Altern. Lab. Anim. 23, 197–209 (1995).

doi: 10.1177/026119299502300205

Thévenot, J. et al. Enterohemorrhagic Escherichia coli O157:H7 survival in an in vitro model of the human large intestine and interactions with probiotic yeasts and resident microbiota. Appl. Environ. Microbiol. 79, 1058–1064 (2013).

pubmed: 23204410 pmcid: 3568547 doi: 10.1128/AEM.03303-12

Etienne-Mesmin, L. et al. In vitro modelling of oral microbial invasion in the human colon. Microbiol. Spectr. 11, e0434422 (2023).

pubmed: 36971547 doi: 10.1128/spectrum.04344-22

Calatayud, M. et al. Salivary and gut microbiomes play a significant role in in vitro oral bioaccessibility, biotransformation, and intestinal absorption of arsenic from food. Environ. Sci. Technol. 52, 14422–14435 (2018).

pubmed: 30403856 pmcid: 6300781 doi: 10.1021/acs.est.8b04457

Marzorati, M. et al. The HMI™ module: a new tool to study the host–microbiota interaction in the human gastrointestinal tract in vitro. BMC Microbiol. 14, 133 (2014).

pubmed: 24884540 pmcid: 4039060 doi: 10.1186/1471-2180-14-133

Shah, P. et al. A microfluidics-based in vitro model of the gastrointestinal human–microbe interface. Nat. Commun. 7, 11535 (2016).

pubmed: 27168102 pmcid: 4865890 doi: 10.1038/ncomms11535

Jalili-Firoozinezhad, S. et al. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nat. Biomed. Eng. 3, 520–531 (2019).

pubmed: 31086325 pmcid: 6658209 doi: 10.1038/s41551-019-0397-0

Xavier, M. et al. From mouth to gut: microfluidic in vitro simulation of human gastro-intestinal digestion and intestinal permeability. Analyst 148, 3193–3203 (2023).

pubmed: 37259813 doi: 10.1039/D2AN02088B

Molero-Abraham, M. et al. Human oral epithelial cells impair bacteria-mediated maturation of dendritic cells and render T cells unresponsive to stimulation. Front. Immunol. 10, 1434 (2019).

pubmed: 31316504 pmcid: 6611079 doi: 10.3389/fimmu.2019.01434

Zhang, Y. et al. Stable reconstructed human gingiva–microbe interaction model: differential response to commensals and pathogens. Front. Cell. Infect. Microbiol. 12, 991128 (2022).

pubmed: 36339338 pmcid: 9631029 doi: 10.3389/fcimb.2022.991128

Shang, L. et al. Multi-species oral biofilm promotes reconstructed human gingiva epithelial barrier function. Sci. Rep. 8, 16061 (2018).

pubmed: 30375445 pmcid: 6207751 doi: 10.1038/s41598-018-34390-y

Shang, L. et al. Commensal and pathogenic biofilms alter Toll-like receptor signaling in reconstructed human gingiva. Front. Cell. Infect. Microbiol. 9, 282 (2019).

pubmed: 31448244 pmcid: 6692492 doi: 10.3389/fcimb.2019.00282

Adelfio, M. et al. Three-dimensional humanized model of the periodontal gingival pocket to study oral microbiome. Adv. Sci. 10, e2205473 (2023).

doi: 10.1002/advs.202205473

Rahimi, C. et al. Oral mucosa-on-a-chip to assess layer-specific responses to bacteria and dental materials. Biomicrofluidics 12, 054106 (2018).

pubmed: 30310527 pmcid: 6158033 doi: 10.1063/1.5048938

Makkar, H., Zhou, Y., Tan, K. S., Lim, C. T. & Sriram, G. Modeling crevicular fluid flow and host–oral microbiome interactions in a gingival crevice-on-chip. Adv. Healthc. Mater. 12, e2202376 (2023).

pubmed: 36398428 doi: 10.1002/adhm.202202376

The oral-gut microbiome axis in health and disease.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Benoit J Kunath (BJ)

Charlotte De Rudder (C)

Cedric C Laczny (CC)

Elisabeth Letellier (E)

Paul Wilmes (P)

Classifications MeSH